Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block for PTSD
NCT05427500Phase 3Enrolling by invitation
- Sponsor
- University of Ottawa Institute of Mental Health Research at The Royal
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bupivacaine hydrochloride 0.75% injection in post-traumatic stress disorder (PTSD), sponsored by University of Ottawa Institute of Mental Health Research at The Royal. Started Mar 2024; status: enrolling by invitation.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05427500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427500.